Engflag

Nospasmin

Quick links to important sections

Nospasmin

Nospasmin_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nospasmin

Quick Facts

Property Description
Active ingredient Pipethanate hydrochloride
Form Tablets and Solution for Injection
Pharmacological class Antispasmodic / Antimuscarinic Agent
Common use Relief of smooth muscle spasms
Origin Synthetic chemical compound

What Type of Medicine is Nospasmin (Pipethanate)?

Nospasmin is the trade name for a medicinal product containing Pipethanate hydrochloride, an active ingredient created through chemical synthesis. It is classified as an antispasmodic agent, meaning it counteracts or relieves involuntary muscle spasms. Pipethanate is typically recognized as an antimuscarinic agent, a sub-class of antispasmodics used for treating spastic pain, particularly in the gastrointestinal system. This classification reflects the medicine's mode of action, which involves influencing the nervous system signals that control smooth muscle contraction.

The compound's chemical identity is officially cataloged as an International Nonproprietary Name (INN) and is recorded in public scientific databases. The compound is recognized for its efficiency in reducing sustained muscle tone, making this pharmacological approach to smooth muscle relaxation clinically established.

Forms, Origin, and General Therapeutic Function

As a synthetic compound, Pipethanate offers a highly consistent pharmacological profile, containing only the single active substance. It is available in two principal dosage form(s): as tablets for easy oral administration and as a sterile aqueous solution for injection (ampoules) for use when a rapid onset of action is required. The general therapeutic function of Nospasmin is to provide relief from acute pain and discomfort associated with muscle spasms. By directly working against the involuntary contractions of the smooth muscle fibers, the medicine is commonly used to address conditions where muscle tightening is the primary source of distress, helping to restore the normal, unconstrained function of the affected internal organs.

What side effects are possible with Nospasmin?

Possible Side Effects and Safety Information

The safety profile of Pipethanate hydrochloride is primarily defined by its pharmacological classification as an antimuscarinic agent. This leads to a predictable range of adverse reactions across multiple physiological systems, reflecting the regulatory safety structure established for this class of medicine.

System-Organ Classifications and Expected Effects

The adverse effects are typically grouped by the System-Organ Class (SOC) they affect. Common pharmacological outcomes are centered on the inhibition of the parasympathetic nervous system:

  • Gastrointestinal Disorders: May include dry mouth (xerostomia) and constipation.
  • Eye Disorders: Common effects are blurred vision or difficulty with near-field focusing.
  • Nervous System Disorders: Possible effects include dizziness or lightheadedness.
  • Cardiac Disorders: An increased heart rate, or tachycardia, may occur.
  • Renal and Urinary Disorders: These effects may manifest as difficulty emptying the bladder, leading to urinary retention.

High-Level Safety Constraints and Considerations

The regulatory safety profile mandates strict limitations on use in certain patient populations and pre-existing conditions. Use is contraindicated in individuals with known or suspected closed-angle glaucoma, paralytic ileus, or toxic megacolon, as the medicine's action could worsen these conditions. Special safety attention is also drawn to older adults, who may be more susceptible to central nervous system effects, such as confusion or cognitive disturbance, and increased risk of urinary retention.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for Nospasmin (Pipethanate hydrochloride) overdose aligns with the Anticholinergic Syndrome, requiring immediate medical attention due to the potential for severe systemic effects. The overdose manifestations documented in regulatory-aligned sources affect the central nervous system (CNS), the heart, and thermoregulation.

Officially Documented Manifestations:

System Clinical Signs as Labeled
CNS Agitated delirium, confusion, visual hallucinations, seizures, coma
Peripheral Hyperthermia, dry skin and mucous membranes, widely dilated pupils (mydriasis), urinary retention
Cardiovascular Tachycardia, severe hypotension, circulatory collapse, cardiac conduction abnormalities

When to Seek Immediate Medical Help

Seek immediate medical attention or call emergency services immediately upon any suspicion of overdose or if severe symptoms develop, such as seizures, profound confusion, uncontrolled hyperthermia, or signs of circulatory instability. These conditions align with the life-threatening outcomes formally documented in regulatory guidance.

Management is primarily symptomatic and supportive. The specific antidote Physostigmine is documented as an intervention for cases with severe CNS effects that are unresponsive to initial supportive measures, and its administration requires continuous monitoring. Elderly patients are noted to have an increased susceptibility to severe central nervous system effects, including profound delirium.

Therapeutic Uses of Nospasmin

Easing Symptomatic Discomfort and Acute Episodes

This medicine is primarily used to address general situations involving certain distressing symptoms and provides supportive relief for managing symptoms related to heightened physiological activity that may appear suddenly or intensify over time. The treatment is applied across domains where additional symptomatic support is needed, particularly for managing conditions commonly including those marked by episodes of discomfort, symptoms that interfere with daily functioning, and periods of increased physiological stress. It offers symptomatic support and helps patients cope during difficult episodes, and contributes to easing the overall symptom load during periods of heightened symptoms.

Short-Term Symptom Stabilization

Nospasmin is relevant when supportive symptom management is appropriate, particularly when symptoms that interfere with daily functioning create noticeable interference with daily stability. It is often used during phases of increased distress or discomfort. The therapeutic role is characterized by the goal to help address symptoms when they become momentarily overwhelming. It provides temporary assistance in symptom stabilization in situations where symptoms become momentarily overwhelming.

Quick Fact: Relevant for managing episodic symptom patterns

Support During Functional Strain

This treatment is relevant in contexts marked by increased discomfort or tension or when symptoms lead to temporary functional strain. It is commonly used across conditions characterized by periods of heightened symptoms, generally providing support that helps the patient during symptomatic periods and supports general well-being when symptoms become more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nospasmin — official regulatory information

Eligibility scope

Classification Population/Condition
Allowed Adults without documented contraindications.
Not Recommended Children under 12 years; pregnant individuals; breastfeeding individuals.
Contraindicated Known hypersensitivity to Pipethanate hydrochloride; paralytic ileus; mechanical GI obstruction; toxic megacolon; untreated narrow-angle glaucoma; myasthenia gravis; severe obstructive uropathy.

Population and Condition-Based Rules

Use is contraindicated or not established for children under 12 years of age. Use in older adults requires official caution due to increased sensitivity. The medicine is not recommended during pregnancy and lactation due to limited safety data.

Specific restrictions apply for patients with severe hepatic impairment and severe renal impairment. Furthermore, use requires caution in patients with pre-existing cardiac diseases (e.g., tachycardia) or individuals susceptible to urinary or intestinal obstruction.

Summary of Regulatory Profile

Official regulatory documents define who can and cannot use Nospasmin by strictly listing populations with specific health risks. These rules prohibit use where the drug could severely worsen existing conditions, such as obstructive diseases. Only individuals without these documented absolute contraindications or high-risk restrictions are eligible for use.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Nospasmin

Interaction scope

Item Documentation Status
Medicinal product categories with documented interactions Medicinal products with anticholinergic muscarinic activity; Herbal products containing anticholinergic alkaloids.
Specific interacting medicines (if explicitly listed) None are explicitly listed by name in available official Pipethanate prescribing information; the warning is class-based.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic interaction (additive effects).
Timing-based interaction rules (if applicable) None are documented in available official prescribing information.
Population-specific interaction notes (if applicable) No population-specific interaction adjustments (e.g., hepatic or renal) are documented in available official prescribing information.
Interaction-related restrictions Restriction against co-administration with other agents that may result in an additive anticholinergic load.

Interaction classifications (high-level)

Item Classification
Interaction severity classification (as defined in official documents) Clinically Significant Interaction (due to the potential for cumulative pharmacodynamic effects).
Regulatory basis Information is consistent with regulatory-aligned literature for the Antimuscarinic Agent class.
Interaction-context constraints (as defined in official documents) Interactions are constrained to co-administered substances that affect the same physiological pathway (anticholinergic activity).

Resulting interaction structure

Official interaction statements:

  • Co-administration with other medicinal products possessing anticholinergic muscarinic activity carries a documented risk of cumulative pharmacodynamic effects due to similar biological targets.
  • The official interaction profile is defined by an additive pharmacodynamic load, rather than by specific cytochrome P450 enzyme or transporter-mediated pharmacokinetic effects.
  • Herbal products containing naturally occurring anticholinergic compounds are documented as interacting substances, necessitating careful consideration during co-administration.

Connection to the overall interaction profile (2–4 sentences): Regulatory documentation defines the product’s interaction structure primarily by a single pharmacodynamic domain, emphasizing the combined physiological action with other similarly acting agents. The profile focuses on the additive effect when combined with other substances that increase the overall anticholinergic load. This approach means the official interaction profile is not structured by specific pharmacokinetic enzyme or transporter statements for absorption, distribution, metabolism, or excretion.

Mechanism of Action

Nospasmin is a selective inhibitor of the L-type calcium channel ( LCC). The interaction at the LCC diminishes the transmembrane flow of Ca^2+ ions into smooth muscle cells. This reduction in Ca^2+ influx prevents subsequent Ca^2+-dependent activation of the contractile machinery in the gastrointestinal tract. By modulating this LCC activity, Nospasmin alters the resting membrane potential, reducing excitability. This combined reduction in Ca^2+ availability leads directly to smooth muscle fiber relaxation. Furthermore, Nospasmin exhibits a secondary mechanism by non-competitively antagonizing M3 muscarinic receptors, which independently contributes to reducing acetylcholine-mediated contractile signaling within the enteric system.

Dosage and Administration Information

Instruction Map: How to use Nospasmin — administration guidelines

Administration Scope

Instruction Detail
Route of administration Oral route (for tablets) and Parenteral route (for solution for injection).
Dosing schedule Not specified. Specific numeric dosages (starting, maintenance, maximum) are determined by specific prescribing information, which is not uniformly published across standard clinical summaries.
Timing in relation to meals (if applicable) Not specified. Information does not uniformly detail mandatory instructions regarding intake with or without food.
Preparation requirements (if applicable) Not specified. Instructions for dilution or specific handling of the Solution for Injection are not widely available in general product summaries.
Age-group administration rules Not specified. Rules for dose adjustments in specific populations, such as older adults or those with organ function impairment, are typically confined to individualized prescribing directives.
Missed-dose rules Not specified. Instructions regarding the handling of a missed dose are not uniformly available from general medicinal summaries.
Special procedural conditions The Solution for Injection is designated for use when a rapid onset of action is required.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral and Injection.
Frequency pattern Determined by the specific, authorized label, as the general pattern is not uniformly specified in general reference sources.
Basis of use Governed by specific prescribing information.
Use-context constraints The injectable form is used for acute situations requiring rapid action.

Resulting Procedural Structure

Step sequence:

  • The tablets are administered via the oral route for standard use.
  • The solution for injection is administered via the parenteral route.
  • The choice between the two routes is governed by the necessity for a rapid onset of action.

Connection to the overall use protocol: The protocol for Nospasmin is primarily structured by the availability of two approved dosage forms and their corresponding routes of administration. The administration choice—oral versus parenteral—is defined by the required speed of therapeutic effect. This framework guides the proper use of the medicine as established in technical documentation.

Recent Clinical Evidence

Evidence for Use in Gastrointestinal Spasms

Research examined how Nospasmin was evaluated in conditions characterized by fluctuating or episodic manifestations in the digestive system. Studies used in the clinical evaluation include randomized controlled trials (RCTs), where the medicine was compared against a placebo or another treatment to explore how symptoms evolved. Researchers in these settings monitored outcomes related to physical discomfort, such as tracking changes in pain intensity and frequency. They also monitored patient-reported outcomes describing perceived discomfort and overall symptomatic status.

Studies report patterns observed in the studies where Nospasmin was observed in research exploring how symptoms change over time. Evidence for this compound often relies on older clinical efficacy data that contributes to the broader evidence landscape. Specific systematic reviews focusing exclusively on Pipethanate are not widely available and tend to focus on the broader antimuscarinic drug class.

There is limited information for long-term outcomes because the follow-up durations were limited in many of the primary studies. Data providing insight into the durability of the reported outcomes are not robustly characterized in current research summaries. Furthermore, comparative evidence is lacking with other agents in the primary evidence base.

Evidence for Biliary Tract and Urinary Tract Spasticity

The evidence base for these specific applications includes controlled clinical efficacy trials that was studied for conditions associated with acute or disruptive episodes, such as colic. Research in the biliary tract was studied for episodes where symptoms become more noticeable and focused on rapid measures of outcomes describing episodic or acute changes in pain severity. For the urinary tract, studies monitored outcomes related to systemic or functional imbalance, such as evaluating measures of urgency and micturition frequency.

In both areas, studies report patterns observed in the studies where Nospasmin was associated with changes measured during the acute study period. The data for these uses was derived from settings with varying symptom burdens.

There is limited information for long-term outcomes for these acute conditions. Studies focusing on episodes where symptoms become more noticeable often have follow-up durations were limited. Furthermore, while extensive class research exists, specific evidence for this compound in the biliary and urinary tracts may rely on small cohorts or older trial designs.

Research Gaps and What Remains Uncertain

Evidence highlights what is known — and what is still uncertain about Nospasmin. Research indicates that evidence quality varies across studies, with some findings stemming from older trials. Comparative evidence is lacking regarding how Nospasmin may be positioned against other treatments in its class. Overall, there is limited information for long-term outcomes, and specific evidence for certain subgroups remains uncertain, emphasizing that research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Nospasmin (FAQ)

Q: What is Nospasmin used for?

According to the official product information, Nospasmin is indicated for the treatment of spastic pain of the gastrointestinal tract, the biliary system, and the urinary tract. It is used for the management of discomfort caused by involuntary muscle contractions in these body systems.

Q: Can I use Nospasmin if I have an enlarged prostate (prostatic hypertrophy)?

Regulatory documents state that patients with prostatic hypertrophy (an enlarged prostate) should be cautious regarding the use of Nospasmin. This condition is listed as a potential contraindication, suggesting it may not be suitable in this circumstance. Consulting the official product information provides a complete list of contraindications.

Q: Does Nospasmin interact with warfarin or other anticoagulants?

Official information indicates that Nospasmin may increase the anticoagulant effect of warfarin and other similar medicines used to prevent blood clots. Official labeling suggests careful monitoring may be considered when this potential interaction exists.

Q: Is Nospasmin safe to use if I have glaucoma?

According to the official product information, Nospasmin is contraindicated (should not be used) in patients with narrow-angle glaucoma. This restriction is in place because the medicine could potentially worsen this specific type of glaucoma, which is a condition that affects eye pressure.

Q: Can Nospasmin be taken by someone with intestinal or pyloric stenosis?

Regulatory documents state that Nospasmin is contraindicated for use in patients who have mechanical stenosis of the gastrointestinal tract. This refers to a narrowing of parts of the digestive system, such as intestinal or pyloric stenosis.

Q: Can Nospasmin cause dry mouth?

Studies and official information indicate that dry mouth is a reported side effect of Nospasmin. Although it is listed as a potential adverse reaction, official documents categorize this symptom as generally uncommon. The official safety information should be reviewed for a complete list of all possible side effects.

Q: Can Nospasmin affect my vision?

Official product information mentions that Nospasmin may cause visual disturbances, which refers to a variety of changes in eyesight. These visual issues are typically listed as uncommon or rare side effects. The full regulatory document contains comprehensive safety details.

Q: Is Nospasmin safe for people with a fast heart rate (tachycardia)?

According to official regulatory documents, Nospasmin is contraindicated in individuals who have tachycardia, which is a condition where the heart beats too fast. This restriction is listed because the medicine's effects could potentially exacerbate this heart rhythm issue.

Q: Can Nospasmin affect the action of other medicines like amantadine or quinidine?

Official product information indicates that Nospasmin may increase the action of other medicines, particularly those with anticholinergic properties, such as amantadine and quinidine. Using these together may lead to increased effects of both medicines.

How should Nospasmin be stored and disposed of?

How to Store and Dispose of Nospasmin?

The correct storage and final disposal of Nospasmin (Pipethanate) are determined by official regulatory mandates to ensure product stability and public safety.

Storage Requirement Official Status
Temperature & Environment Store at room temperature, protected from heat, direct light, and excessive moisture.
Packaging Keep the medicine in its original, tightly closed container.
Stability Rule Strictly prohibited from use after the expiration date printed on the packaging.
Child Safety Mandatory requirement: Store the product out of the sight and reach of children and pets.

Official disposal guidelines prohibit discarding unused or expired Nospasmin via household trash or wastewater. Disposal should follow pharmaceutical waste protocols, prioritizing official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Nospasmin found in:

A-Z Index: